Skip to main content
SpringerLink
Log in

Comment on: “Regorafenib: Start Low and Go Slow”

  • Letter to the Editor
  • Published:
Targeted Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Tabchi S, Ghosn M (2015) Regorafenib: start low and go slow. Target Oncol 10:445–7

    Article  CAS  PubMed  Google Scholar 

  2. Grothey A (2015) Regorafenib in metastatic colorectal cancer: optimal dosing and patient selection recommendations. Clin Adv Hematol Oncol 13:514–7

    PubMed  Google Scholar 

  3. Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–67

    Article  CAS  PubMed  Google Scholar 

  4. Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M et al (2012) Regorafenib (BAY 73–4506) in advanced colorectal cancer: a phase I study. Br J Cancer 106:1722–7

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–12

    Article  CAS  PubMed  Google Scholar 

  6. Li J, Qin S, Xu R, Yau TC, Ma B, Pan H et al (2015) Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 16:619–29

    Article  CAS  PubMed  Google Scholar 

  7. Van Cutsem E, Ciardiello F, Seitz JF, Hofheinz R, Verma U, Garcia-Carbonero R et al (2015) Results from the large, open-label phase 3b CONSIGN study of regorafenib in patients with previously treated metastatic colorectal cancer (abstract no. LBA-05). Ann Oncol 26(Suppl 4):iv118

  8. Goldstein DA, Ahmad BB, Chen Q, Ayer T, Howard DH, Lipscomb J et al (2015) Cost-effectiveness analysis of regorafenib for metastatic colorectal cancer. J Clin Oncol 33(32):3727–32

  9. De La Fouchardiere C, Paule B, Burtin P, Wallet J, Tougeron D, Dourthe LM et al. Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study; abstract 2095. Eur Cancer Congr. 2015

  10. Kramar A, Paule B, Burtin P, Tougeron D, Desseigne F, Dourthe LM et al. Prognostic score (REGOSCORE) for survival after regorafenib (RE) treatment for patients (pts) with pretreated metastatic colorectal cancer (mCRC); abstract 2090. Eur Cancer Congr. 2015

  11. Wong ALA, Lim JSJ, Sinha A, Gopinathan A, Lim R, Tan CS et al (2015) Tumour pharmacodynamics and circulating cell free DNA in patients with refractory colorectal carcinoma treated with regorafenib. J Transl Med 13:57

    Article  PubMed  PubMed Central  Google Scholar 

  12. Tabernero J, Lenz HJ, Siena S, Sobrero A, Falcone A, Ychou M et al (2015) Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. Lancet Oncol 16:937–48

    Article  CAS  PubMed  Google Scholar 

  13. Jiang X, Pissaloux D, De La Fouchardiere C, Desseigne F, Wang Q, Attignon V et al (2015) The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value. Oncotarget 6(28):26388–99

    Article  PubMed  PubMed Central  Google Scholar 

  14. Grothey A, George S, Van Cutsem E, Blay JY, Sobrero A, Demetri GD (2014) Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist 19:669–80

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We would like to thank Sophie Darnis (Centre Léon Bérard, Lyon, France) for editorial assistance.

Author information

Authors and Affiliations

  1. Centre Léon Bérard-Université Lyon I, Lyon, France

    Christelle de la Fouchardière

Authors
  1. Christelle de la Fouchardière
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christelle de la Fouchardière.

Ethics declarations

Funding

None.

Conflict of Interest

Christelle de la Fouchardière has received consulting fees and support for travel to meetings from Bayer HealthCare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

de la Fouchardière, C. Comment on: “Regorafenib: Start Low and Go Slow”. Targ Oncol 11, 123–125 (2016). https://doi.org/10.1007/s11523-015-0407-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11523-015-0407-4

Keywords

Search

Navigation